+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 69 Actively Recruiting clinical trials

Y

Actively Recruiting

Healthy Volunteer

Researchers are conducting the 100-Year Human Aging Study to observe and validate multiple health measurements over time in adults aged 18 and older. This observational trial aims to determine which physiological, cognitive, social, and environmental measures best predict mortality, serious diseases, and functional disability. The study addresses the lack of validated longevity markers by following participants longitudinally until death, gathering comprehensive clinical and lifestyle data. Participants undergo thorough multi-system clinical screening that includes cardiopulmonary exercise testing, body composition analysis by DEXA, heart and lung function tests, neurocognitive and sensory assessments, metabolic testing, and detailed personal histories. Screening can occur at fixed sites, mobile units, or online, with varying levels of participation from single tests to full two-visit comprehensive evaluations. Investigational constructs like biological age estimates and predicted death age are generated but remain research hypotheses. During the study, participants are encouraged to return for repeat testing to build health trajectories over their lifespan. Researchers collect data through clinical assessments, laboratory tests, and imaging, monitoring outcomes such as all-cause and cause-specific mortality, incident serious health events, chronic diseases, functional independence, disability, and health behavior changes. The study aims for long-term follow-up, potentially up to 100 years, with periodic contact and data collection to validate longevity measures and predictive models.

Age: 18Years +All Genders
1 location
Y

Actively Recruiting

Researchers are comparing the survival rates of different ceramic dental implants in adults with missing or hopeless teeth. This observational study focuses on two types of CeraRoot ceramic implants one-piece and two-piece TL models. The study aims to determine if there are significant differences in implant survival and to identify any complications associated with the procedures in these groups. The study involves patients from two dental centers in Barcelona, Spain, and Boulder, Colorado, USA. Participants will receive either one-piece or two-piece CeraRoot ceramic dental implants. These implants are specially designed for patients with metal allergies or chronic illnesses related to metal allergies. The study will follow patients for at least 12 months after enrollment to monitor implant survival and complications. During the study, researchers will collect information on implant survival rates and any complications occurring within one year after treatment. Participants will undergo dental assessments to evaluate implant status and oral health. The studys main outcome is the survival rate of the implants over 12 months or longer. This long-term follow-up helps understand the performance and safety of these ceramic dental implants in real-world clinical settings.

Age: 18Years +All Genders
2 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety, tolerability, and lasting effects of ALKS 2680 tablets in adults with Narcolepsy Type 1, Narcolepsy Type 2, or Idiopathic Hypersomnia. This study involves participants who have completed earlier ALKS 2680 parent studies and aims to continue monitoring treatment impact over an extended period. Participants receive oral ALKS 2680 tablets once daily at doses ranging from 4 mg to 18 mg. The study follows a non-randomized, open-label design, and includes three groups based on the specific condition Narcolepsy Type 1, Narcolepsy Type 2, and Idiopathic Hypersomnia. The treatment duration extends up to 248 weeks, allowing long-term observation of the medications effects. During the study, participants undergo regular assessments including monitoring for adverse events, changes in sleep latency using the Maintenance of Wakefulness Test, sleepiness severity via the Epworth Sleepiness Scale, weekly cataplexy rate, and idiopathic hypersomnia severity. Safety and treatment effects are tracked throughout the study period, which may last up to nearly five years, ensuring ongoing evaluation of participant health and treatment durability.

Age: 18Years - 70YearsAll GendersPhase 2Phase 3
50 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of HBS-301 in adults aged 18 years and older who have idiopathic hypersomnia IH, a condition characterized by excessive daytime sleepiness EDS. This Phase 3 clinical trial is randomized, double-blind, and placebo-controlled, aiming to better understand how HBS-301 affects the severity of sleepiness and other IH symptoms compared to placebo. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may choose to join an optional 1-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by 30 days of safety follow-up after treatment ends. During the trial, participants will have regular assessments including questionnaires measuring sleepiness severity using the Epworth Sleepiness Scale and other scales evaluating IH symptoms, sleep inertia, fatigue, cognition, quality of life, and work productivity. Safety monitoring includes tracking any adverse events throughout the 16 months of the study. Participants will be involved in scheduled visits for evaluations and treatment adherence, with the primary focus on changes in daytime sleepiness severity over the 8-week treatment period.

Age: 18Years +All GendersPhase 3
42 locations
P

Actively Recruiting

Researchers are conducting a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of HBS-301 in adults aged 18 years and older with narcolepsy. The study focuses on treating excessive daytime sleepiness EDS, cataplexy, sleepinesswakefulness, and fatigue in this population. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may opt into a one-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by the treatment phases, and concludes with a 30-day safety follow-up. During the study, participants will undergo various assessments including the Epworth Sleepiness Scale to measure changes in daytime sleepiness, evaluations of cataplexy frequency, fatigue levels, sleepinesswakefulness tests, and quality of life questionnaires. Safety will be monitored throughout the entire study duration of approximately 16 months. Participants will have scheduled visits for assessments during each phase to track treatment effects and safety.

Age: 18Years +All GendersPhase 3
53 locations
A

Actively Recruiting

Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.

Age: 18Years +All GendersPhase 3
366 locations
E

Actively Recruiting

Alzheimers disease is a progressive and irreversible brain disorder that commonly causes dementia in older adults. It begins with mild memory problems such as misplacing items or forgetting events and can worsen to confusion, agitation, and loss of independence. This research aims to test the safety, effects, and how the body processes ABBV-1758, an investigational drug being studied for Alzheimers disease in a multi-stage clinical trial. Participants receive ABBV-1758 or a placebo through intravenous or subcutaneous injections once every four weeks for 24 weeks. The study includes three stages Stage A with multiple dose levels using a 41 randomization, Stage B expanding dosing cohorts, and Stage C enrolling Japanese and Chinese participants with the same randomization. After treatment, participants are followed for 12 weeks and may join a blinded 12-month extension depending on amyloid PET scan results. During the study, participants attend regular clinic visits for medical assessments, blood tests, and questionnaires to monitor safety and effects. Researchers measure outcomes like adverse events, lab test changes, brain amyloid levels, and drug concentration in the blood over approximately 40 weeks. The total participation time includes treatment, follow-up, and possible extension periods.

Age: 50Years - 90YearsAll GendersPhase 1Phase 2
13 locations
C

Actively Recruiting

Researchers are evaluating two treatment combinations for patients with BRAF-V600 mutant melanoma that has spread to the brain. This phase II trial compares encorafenib, binimetinib, and nivolumab with ipilimumab and nivolumab to see which is more effective in shrinking and controlling brain metastases from melanoma. The study also aims to assess survival, response rates, duration of response, and toxicity of these treatments. Participants are randomly assigned to one of two groups. One group receives encorafenib once daily by mouth, binimetinib twice daily by mouth, and nivolumab intravenously on the first day of each 28-day cycle. The other group receives nivolumab intravenously on day one of all cycles and ipilimumab intravenously over 30 minutes on day one of the first four 21-day cycles, then nivolumab every 28 days. Treatment continues until disease progression or unacceptable side effects. During the study, participants undergo brain and tumor imaging, physical exams, and laboratory tests. After completing treatment, they are followed every six months for two years and then annually up to three years from randomization. Researchers monitor progression-free survival, overall survival, tumor response, brain metastasis response, and safety. Samples of tissue, cerebrospinal fluid, stool, and blood are collected for future research.

Age: 18Years +All GendersPhase 2
331 locations
E

Actively Recruiting

Researchers are evaluating ALKS 2680 tablets in adults with Narcolepsy Type 1 NT1 to measure reductions in daytime sleepiness, sudden muscle tone loss cataplexy, and overall disease symptoms. This phase 3 clinical trial compares the effects of ALKS 2680 with placebo tablets to assess their impact on these key aspects of NT1. Participants are randomly assigned to one of three groups a placebo group or one of two different dose groups of ALKS 2680 tablets. All participants take their assigned oral tablets daily for 12 weeks. The study uses a triple-blind design, meaning that participants, investigators, and others involved do not know which treatment is being given. During the 12-week treatment, participants will be monitored for changes in sleep latency using the Maintenance of Wakefulness Test, daytime sleepiness via the Epworth Sleepiness Scale, weekly cataplexy rates, and other cognitive and fatigue assessments. Safety is tracked through the incidence of treatment-emergent adverse events up to 14 weeks. Outcome measures also include patient global impressions and narcolepsy severity scales to evaluate overall disease impact.

Age: 18Years - 70YearsAll GendersPhase 3
44 locations
E

Actively Recruiting

Researchers are evaluating the effects of ALKS 2680 tablets on reducing daytime sleepiness and symptoms in adults diagnosed with Narcolepsy Type 2 NT2. This Phase 3, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of three different doses of ALKS 2680 compared with placebo tablets. The study is sponsored by Alkermes, Inc. and uses a parallel design to compare outcomes. Participants are randomly assigned to receive one of three dose levels of ALKS 2680 tablets or a placebo, taken orally once daily for 12 weeks. The study includes a triple-blind approach to ensure unbiased results. The primary focus is on measuring changes in mean sleep latency using the Maintenance of Wakefulness Test MWT from baseline through Week 12. Secondary outcome measures include assessments of sleepiness, cognitive complaints, fatigue, and global impression scales. Throughout the 12-week treatment, participants will undergo various evaluations such as the Epworth Sleepiness Scale, Patient Global Impression-Severity scale, and Psychomotor Vigilance Task, among others. Safety is monitored by recording treatment emergent adverse events up to 14 weeks. This study includes adults aged 18 to 70 years with a confirmed diagnosis of NT2. Overall participation spans just over 12 weeks, with regular assessments to track symptom changes and treatment effects.

Age: 18Years - 70YearsAll GendersPhase 3
44 locations

1-10 of 69

1